

2 October 2018

LEI No. 213800QIPVTK5ES5UU36



Scapa Group plc (“Scapa” or “the Group”)

**Completion of Acquisition of Systagenix Advanced Wound Dressing Facility in Gargrave
Entering a 5-year exclusive manufacturing and supply agreement**

Further to the announcement made on 13 September 2018, Scapa Group plc (AIM: SCPA) is pleased to announce that its acquisition of the share capital of Systagenix Wound Management Manufacturing Limited completed on 1 October 2018. In addition, Scapa and Acelity have now entered into the exclusive five-year manufacturing and supply agreement for Systagenix advanced wound care products that are currently manufactured in the Gargrave facility, with immediate effect.

For further information:

Scapa Group plc	
Heejae Chae – Group Chief Executive	0161 301 7430
Oskar Zahn – Chief Financial Officer	
Numis Securities Limited	020 7260 1000
(Nominated Adviser and Joint Broker)	
Richard Thomas/Mark Lander	
Berenberg	020 3207 7800
(Joint Broker)	
Chris Bowman	
Weber Shandwick Financial PR	020 7067 0000
Nick Osborne	